Notice of results and Investor presentation

Tissue Regenix

06/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230306:nRSF9168Ra&default-theme=true

RNS Number : 9168R  Tissue Regenix Group PLC  06 March 2023

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

 

Notice of results and Investor presentation

( )

Tissue Regenix (AIM: TRX), the regenerative medical device company, will
announce its final results for the year ended 31 December 2022 on Tuesday 21
March 2023.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer,
will host a live online presentation relating to the final results via the
Investor Meet Company platform at 1.30pm on Thursday 23 March 2023. The
presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation
here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
(https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor)

 

Investors who already follow Tissue Regenix on the Investor Meet Company
platform will be de facto invited.

 

For more information:

 

 Tissue Regenix Group plc                                             www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                                 Via Walbrook PR

 finnCap Ltd (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR & IR)      Tel: +44(0)20 7933 8780
 Alice Woodings / Lianne Applegarth   TissueRegenix@walbrookpr.com

 

 

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of
regenerative medicine. The Company's patented decellularisation technology
('dCELL®') removes DNA and other cellular material from animal and human soft
tissue, leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech
company that specialises in regenerative medicine and is dedicated to the
development of high quality, innovative tissue scaffolds, which can enhance
healing opportunities in defects created by trauma and disease. CellRight®'s
human tissue products may be used in spine, trauma, general orthopaedic,
dental and ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFITVTIVIIV